Bimler Lynn, Song Amber Y, Le Duy T, Murphy Schafer Ashleigh, Paust Silke
1Center for Human Immunobiology, Department of Pediatrics, Texas Children's Hospital, Houston, TX 77030 USA.
2Graduate Program in Immunology, Baylor College of Medicine, Houston, TX 77030 USA.
Immun Ageing. 2019 Sep 2;16:23. doi: 10.1186/s12979-019-0162-y. eCollection 2019.
Influenza virus infection causes significant morbidity and mortality worldwide. Humans fail to make a universally protective memory response to influenza A because of high mutation rates in the immune-dominant influenza epitopes. We seek the development of a universal influenza A vaccine. The extracellular domain of the M2-ion channel (M2e) is an ideal antigenic target, as it is highly conserved, has a low mutation rate, and is essential for viral entry and replication. Considering the potential of a universal influenza vaccine for lifelong protection, we aimed to examine this potential using a recently published gold nanoparticle M2e vaccine with CpG as an adjuvant (AuNP-M2e + sCpG). Intranasal vaccination induces an M2e-specific memory response, which is protective against lethal infection with H1N1, H3N2, and H5N1 serotypes, in young BALB/c mice. Protection with AuNP-M2e + sCpG has been published up to 8 months after vaccination. However, the highest risk population during most influenza seasons is adults over 65 years old. Additionally, the efficacy of many vaccines decrease after aging and requiring booster vaccinations to remain effective.
To determine if the AuNP-M2e + sCpG vaccine is a viable option as a universal vaccination capable of protection through geriatric age, we tested if the AuNP-M2e + sCpG vaccination loses efficacy after aging mice to geriatric age (over 18 months). Our data shows that mice aged 15 months after vaccination (~ 18-21 months old) retain significant M2e-specific antibody titers in total IgG, IgG1, IgG2a, and IgG2b. These mice are significantly protected from lethal influenza challenge (H1N1, 8.3 PFU). Further, these antibody titers increase upon infection with influenza A and remain elevated for 3 months, suggesting the elderly mice retain effective M2e-specific memory B cells.
Our results demonstrate that protective M2e-specific memory in mice developed at a young age can persist until geriatric age. Additionally, this memory is protective and M2e-specific B cells produced by vaccination with AuNP-M2e + sCpG are maintained and functional. If the results of this study persist in humans, they suggest that a universal influenza A vaccine could be administered early in life and maintain lifelong protection into geriatric age.
流感病毒感染在全球范围内导致了显著的发病率和死亡率。由于免疫优势流感表位的高突变率,人类无法对甲型流感产生普遍的保护性记忆反应。我们致力于开发一种通用的甲型流感疫苗。M2离子通道(M2e)的细胞外结构域是一个理想的抗原靶点,因为它高度保守、突变率低,并且对于病毒进入和复制至关重要。考虑到通用流感疫苗具有终身保护的潜力,我们旨在使用最近发表的以CpG作为佐剂的金纳米颗粒M2e疫苗(AuNP-M2e + sCpG)来检验这种潜力。鼻内接种疫苗可诱导M2e特异性记忆反应,在年轻的BALB/c小鼠中,这种反应对H1N1、H3N2和H5N1血清型的致死性感染具有保护作用。接种AuNP-M2e + sCpG后的保护作用已在接种后长达8个月内得到报道。然而,在大多数流感季节中,风险最高的人群是65岁以上的成年人。此外,许多疫苗的效力在衰老后会降低,需要加强接种才能保持有效性。
为了确定AuNP-M2e + sCpG疫苗作为一种能够在老年期提供保护的通用疫苗是否可行,我们测试了在将小鼠衰老至老年期(超过18个月)后,AuNP-M2e + sCpG接种疫苗的效力是否会丧失。我们的数据表明,接种疫苗后15个月龄的小鼠(约18 - 21个月大)在总IgG、IgG1、IgG2a和IgG2b中保留了显著的M2e特异性抗体滴度。这些小鼠受到显著保护,免受致死性流感攻击(H1N1,8.3 PFU)。此外,这些抗体滴度在感染甲型流感后会升高,并在3个月内保持升高,这表明老年小鼠保留了有效的M2e特异性记忆B细胞。
我们的结果表明,幼年小鼠中产生的保护性M2e特异性记忆可以持续到老年期。此外,这种记忆具有保护作用,并且通过接种AuNP-M2e + sCpG产生的M2e特异性B细胞得以维持并发挥功能。如果这项研究的结果在人类中也成立,那么这表明一种通用的甲型流感疫苗可以在生命早期接种,并在老年期维持终身保护。